// App-Quantinova.ai

OP0169 : SARILUMAB FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS: RESULTS OF A PHASE 2, RANDOMIZED. DOUBLE-BLIND, PLACEBO-CONTROLLED, INTERNATIONAL STUDY (ALIGN)

Researchers

Presenter

  • J. Sieper

Principal Investigators

  • R.D. Inman

  • S. Badalamenti

  • A. Radin

  • J. Braun

Medical Centers

  • Institute of Pathology, Charite Universitatsmedizin Berlin, Berlin, Germany

  • Rheumazentrum Ruhrgebiet, Herne, Germany

  • Immunology, The Toronto Hospital Western Division, Toronto, Canada

Locations

  • Germany

  • Canada

Companies

  • Regeneron Pharmaceut

  • Sanofi S.A.

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Ankylosing spondylitis

  • Spondyloarthritis

  • Neutropenia

Biomarkers

  • Alanine transaminase

  • High sensitivity C-reactive protein

Drug/Treatment

  • Sarilumab

  • Ranitidine

  • Mofezolac

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved